Articles published by EMulate Therapeutics, Inc.

EMulate Therapeutics Opens Community Investment Round on Wefunder, Offering Public Access to Groundbreaking Digital Therapeutics Platform

October 28, 2025

From EMulate Therapeutics, Inc.

Via GlobeNewswire

EMulate Therapeutics Inc. Announces Publication of Pre-Clinical Mouse Model Demonstrating Direct Evidence of Immune Checkpoint Receptor Knock-Down in a Mouse Glioblastoma Model

August 20, 2024

From EMulate Therapeutics, Inc.

Via Business Wire

EMulate Therapeutics Announces the Publication of the Evaluation of Its Ultra-Low Radiofrequency Energy Device in Murine Model of Glioblastoma in BMC Bioelectric Medicine

April 11, 2024

From EMulate Therapeutics, Inc.

Via Business Wire

EMulate Therapeutics Inc. Announces Publication of Clinical Results at the SNO 2023 Conference: GBM and DIPG

November 14, 2023

From EMulate Therapeutics, Inc.

Via Business Wire

EMulate Therapeutics Announces the Publication of Its Phase I/II Results in CNS Oncology: “An Expanded Safety/Feasibility Study of the EMulate Therapeutics Voyager™ System in Patients with Recurrent Glioblastoma”

July 18, 2023

From EMulate Therapeutics, Inc.

Via Business Wire

EMulate Therapeutics Announces Brett Greene, Veteran in the Psychedelic and Cannabinoid Biotechnology Industry, as a Company Advisor

July 18, 2023

From EMulate Therapeutics, Inc.

Via Business Wire

EMulate Therapeutics Announces the Incorporation of a Third Wholly Owned Subsidiary

February 23, 2022

From EMulate Therapeutics, Inc.

Via AccessWire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.